Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer

Fig. 2

Nomogram predicting the probability of pathological complete response (pCR) after neoadjuvant chemotherapywith the regimen of cyclophosphamide, epirubicin and 5-fluorouracil; cyclophosphamide, epirubicin and 5-fluorouracil followed by paclitaxel or docetaxel and epirubicin; navelbine and epirubicin; or paclitaxel and carboplatin or paclitaxel and cisplatin

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us